6Dohrek, Thor P. Neuroendocrine activation as a target of modem chronic heart failure pharmacotherapy [ J ]. Acta Pol Pharm, 2011, 68(3): 307.
7Lund L H, Benson L, Dahlstrm U, et al. Association be- tween use of renin- angiotensin system antagonists and mor- tality in patients with heart failure and preserved ejection frac- tion[J]. JAMA, 2012, 308(20): 2108.
9Cice G, Di Benedetto A, D'Isa S, et al. Effects of telmisar- tan added to Angiotensin - converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double- blind, placebo- controlled trial[J ]. J Am Coll Cardiol, 2010, 56(21) : 1701.
9[1]Massie B M, Shah N B. Evolving trends in the epi demiologic failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J,1997,133:703-712.
10[2]Paker M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J AmCollCardiol, 1992,20:248-252.
3Yasue Fukushima,Michio Nakanishi,Hiroshi Nonogi.Assessment of Plasma miRNAs in Congestive Heart Failure. Circulation Journal . 2011
4Choueiri Toni K,Mayer Erica L,Je Youjin,Rosenberg Jonathan E,Nguyen Paul L,Azzi Georges R,Bellmunt Joaquim,Burstein Harold J,Schutz Fabio A B.Congestive heart failure risk in patients with breast cancer treated with bevacizumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . 2011
